Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 15 Oct 2021 |
| Grant of Restricted Stock Units and Warrants to Employees in Genmab | 7 Oct 2021 |
| Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021) | 1 Oct 2021 |
| Genmab A/S has published its Articles of Association | 22 Sept 2021 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 21 Sept 2021 |
| Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer | 20 Sept 2021 |